Syros Pharmaceuticals (SYRS) Stock Rating Upgraded by BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a buy rating to a strong-buy rating in a research note published on Friday.

A number of other research analysts have also recently issued reports on SYRS. Oppenheimer set a $13.00 price objective on shares of Syros Pharmaceuticals and gave the company a buy rating in a research note on Thursday, March 7th. ValuEngine lowered shares of Syros Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, January 2nd. HC Wainwright restated a hold rating and issued a $10.00 target price on shares of Syros Pharmaceuticals in a research report on Friday, March 8th. Roth Capital set a $14.00 target price on shares of Syros Pharmaceuticals and gave the company a buy rating in a research report on Sunday, December 2nd. Finally, Wedbush restated an outperform rating and issued a $13.00 target price on shares of Syros Pharmaceuticals in a research report on Monday, December 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Syros Pharmaceuticals has a consensus rating of Buy and a consensus price target of $15.29.

Shares of NASDAQ:SYRS opened at $9.11 on Friday. The company has a market capitalization of $298.54 million, a P/E ratio of -4.77 and a beta of 1.22. Syros Pharmaceuticals has a 1 year low of $5.17 and a 1 year high of $13.86.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.05). The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $0.40 million. Syros Pharmaceuticals had a negative net margin of 3,038.00% and a negative return on equity of 64.43%. On average, equities analysts anticipate that Syros Pharmaceuticals will post -2.1 EPS for the current fiscal year.

In other Syros Pharmaceuticals news, major shareholder Venture Fund Vii L.P. Arch sold 164,583 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $6.80, for a total value of $1,119,164.40. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 27.80% of the company’s stock.

Several large investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of Syros Pharmaceuticals by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 249,668 shares of the company’s stock worth $1,390,000 after purchasing an additional 23,234 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Syros Pharmaceuticals by 62.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 244,080 shares of the company’s stock worth $1,360,000 after purchasing an additional 93,728 shares during the period. D. E. Shaw & Co. Inc. lifted its holdings in shares of Syros Pharmaceuticals by 763.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 88,882 shares of the company’s stock worth $496,000 after purchasing an additional 78,591 shares during the period. Bank of America Corp DE lifted its holdings in shares of Syros Pharmaceuticals by 205.9% during the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after purchasing an additional 11,711 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Syros Pharmaceuticals by 3.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,561 shares of the company’s stock worth $683,000 after purchasing an additional 3,900 shares during the period. Institutional investors own 67.87% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Featured Article: What is the LIBOR?

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

FY2019 EPS Estimates for W W Grainger Inc  Cut by Gabelli
FY2019 EPS Estimates for W W Grainger Inc Cut by Gabelli
Exane Derivatives Purchases 870 Shares of Cigna Corp
Exane Derivatives Purchases 870 Shares of Cigna Corp
Waters  Given New $209.00 Price Target at Robert W. Baird
Waters Given New $209.00 Price Target at Robert W. Baird
10,637 Shares in Vale SA  Acquired by Mercer Global Advisors Inc. ADV
10,637 Shares in Vale SA Acquired by Mercer Global Advisors Inc. ADV
Zacks: Analysts Expect Douglas Emmett, Inc.  to Announce $0.52 EPS
Zacks: Analysts Expect Douglas Emmett, Inc. to Announce $0.52 EPS
Whitestone REIT Plans Monthly Dividend of $0.10
Whitestone REIT Plans Monthly Dividend of $0.10


© 2006-2019 Ticker Report